A Study of LY2523355 in Participants With Breast Cancer

NCT01416389 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

39

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: LY2523355
DRUG: ixabepilone
DRUG: pegfilgrastim
DRUG: filgrastim

Sponsor

Eli Lilly and Company